PROTHENAMEDAFFAIRS.COM KEYWORD DENSITY CHECKER

Total words: 1638 | 2-word phrases: 428 | 3-word phrases: 474 | 4-word phrases: 485

PAGE INFO

Title Try to keep the title under 60 characters (15 characters)
Home | Prothena
Description Try to keep the meta description between 50 - 160 characters (33 characters)
Prothena | Heal, Cure and Prevent
Keywords Meta keywords are not recommended anymore (33 characters)
Healthcare learning, prothena, prothenamedaffairs, prothena med affairs, med affairs, medical affairs, Amyloidosis, Neuroscience, AL Amyloidosis
H1 No H1 tag on the page (0 characters)

ONE WORD PHRASES 251 Words

# Keyword H1 Title Des Volume Position Suggest Frequency Density
1the187.17%
2to155.98%
3amyloidosis114.38%
4of114.38%
5in103.98%
6and93.59%
7al83.19%
8prothena83.19%
9learn83.19%
10more83.19%

TWO WORD PHRASES 428 Words

# Keyword H1 Title Des Volume Position Suggest Frequency Density
1learn more81.87%
2al amyloidosis61.40%
3clinical trial61.40%
4on the40.93%
5commitment to40.93%
6investigational drug30.70%
7are a30.70%
8approved by30.70%
9in a30.70%
10regulatory authority30.70%
11about prothena30.70%
12the phase30.70%
13patients with20.47%
14check out20.47%
15drugs and20.47%
16us healthcare20.47%
17of birtamimab20.47%
18prothena is20.47%
19are investigational20.47%
20monoclonal antibody20.47%

THREE WORD PHRASES 474 Words

# Keyword H1 Title Des Volume Position Suggest Frequency Density
1approved by any20.42%
2the phase 320.42%
3resources key publications20.42%
4commitment to neuroscience20.42%
5any regulatory authority20.42%
6you are a20.42%
7newly diagnosed patients20.42%
8commitment to al20.42%
9phase 3 vital20.42%
10are investigational drugs20.42%
11investigational drugs and20.42%
12drugs and not20.42%
13the amyloidosis channel20.42%
14approach to drug20.42%
15prothena’s approach to20.42%
16and not approved20.42%
17not approved by20.42%
18prothena’s commitment to20.42%
19under investigation for10.21%
20a nextgeneration subcutaneously10.21%
21antibody under investigation10.21%
22monoclonal antibody under10.21%
23antiaΒ monoclonal antibody10.21%
24delivered antiaΒ monoclonal10.21%
25in neuroscience prx01210.21%
26is a nextgeneration10.21%
27prx012 is a10.21%
28neuroscience prx012 is10.21%
29treatment of alzheimer’s10.21%
30latest in neuroscience10.21%

FOUR WORD PHRASES 485 Words

# Keyword H1 Title Des Volume Position Suggest Frequency Density
1are investigational drugs and20.41%
2drugs and not approved20.41%
3and not approved by20.41%
4the phase 3 vital20.41%
5prothena’s approach to drug20.41%
6investigational drugs and not20.41%
7in neuroscience prx012 is10.21%
8latest in neuroscience prx01210.21%
9the body learn more10.21%
10in the body learn10.21%
11deposits in the body10.21%
12amyloid deposits in the10.21%
13clear amyloid deposits in10.21%
14and clear amyloid deposits10.21%
15target and clear amyloid10.21%
16monoclonal antibody designed to10.21%
17selectively target and clear10.21%
18investigational monoclonal antibody designed10.21%
19prx012 is a nextgeneration10.21%
20an investigational monoclonal antibody10.21%
21is an investigational monoclonal10.21%
22birtamimab is an investigational10.21%
23of action of birtamimab10.21%
24mechanism of action of10.21%
25the mechanism of action10.21%
26of the mechanism of10.21%
27neuroscience prx012 is a10.21%
28monoclonal antibody under investigation10.21%
29is a nextgeneration subcutaneously10.21%
301 ascent1 and ascent210.21%
31al amyloidosis publications neuroscience10.21%
32contact al amyloidosis publications10.21%
33learn more useful links10.21%
34ongoing learn more useful10.21%
35are ongoing learn more10.21%
36prx012 are ongoing learn10.21%
37with prx012 are ongoing10.21%
38trials with prx012 are10.21%
39clinical trials with prx01210.21%
40phase 1 ascent1 and10.21%

EXTERNAL LINKS

# URL Whois Check
1https://www.prothena.com/terms-of-use/ Whoisprothena.com
2 https://www.prothena.com/privacy-policy/ Whoisprothena.com